| 1 |
Naidoo J，Santos-Zabala ML，Iyriboz T，et al. Large cell neuroendocrine carcinoma of the lung：Clinico-pathologic features，treatment，and outcomes［J］. Clin Lung Cancer，2016，17（5）：e121-e129.
|
| 2 |
García-Yuste M，Matilla JM，Alvarez-Gago T，et al. Prognostic factors in neuroendocrine lung tumors：a spanish multicenter study.spanish multicenter study of neuroendocrine tumors of the lung of the spanish society of pneumonology and thoracic surgery （EMETNESEPAR）［J］. Ann Thorac Surg，2000，70（1）：258-263.
|
| 3 |
Wang J，Zhou C，Yao W，et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer （ CAPSTONE-1 ）：a multicentre，randomised，double-blind，placebo-controlled，phase 3 trial［J］.Lancet Oncol，2022，23（6）：739-747.
|
| 4 |
Lantuejoul S，Fernandez-Cuesta L，Damiola F，et al. New molecular classification of large cell neuroendocrine carcinoma and small cell lung carcinoma with potential therapeutic impacts［J］. Transl Lung Cancer Res，2020，9（5）：2233-2244.
|
| 5 |
Fasano M，Della Corte CM，Papaccio F，et al. Pulmonary large-cell neuroendocrine carcinoma：From epidemiology to therapy［J］. J Thorac Oncol，2015，10（8）：1133-1141.
|
| 6 |
Fabbri A，Cossa M，Sonzogni A，et al. Thymus neuroendocrine tumors with CTNNB1 gene mutations，disarrayed ß-catenin expression，and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor：a paradigm shift［J］. Virchows Arch，2017，471（1）：31-47.
|
| 7 |
Hanna N，Johnson D，Temin S，et al. Systemic therapy for stage Ⅳnon-small-cell lung cancer：american society of clinical oncology clinical practice guideline update summary［J］. J Oncol Pract，2017，13（12）：832-837.
|
| 8 |
中国临床肿瘤学会小细胞肺癌专家委员会，中国医师协会肿瘤多学科诊疗专业委员会. 小细胞肺癌免疫治疗专家共识（2025版）［J］. 中华肿瘤杂志，2025，47（1）：65-75.
|
| 9 |
Le Treut J，Sault MC，Lena H，et al. Multicentre phase Ⅱstudy of cisplatin-etoposidechemotherapyforadvancedlarge-cell neuroendocrine lung carcinoma：the GFPC 0302 study［J］. Ann Oncol，2013，24（6）：1548-1552.
|
| 10 |
Derks JL，van Suylen RJ，Thunnissen E，et al. Chemotherapy for pulmonary large cell neuroendocrine carcinomas：does the regimen matter？ ［J］. Eur Respir J，2017，49（6）：1601838.
|
| 11 |
Zhang JT，Li Y，Yan LX，et al. Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma：A multi-center retrospective study［J］. Lung Cancer，2020，139：118-123.
|
| 12 |
Sun JM，Ahn MJ，Ahn JS，et al. Chemotherapy for pulmonary large cell neuroendocrine carcinoma：similar to that for small cell lung cancer or non-small cell lung cancer？ ［J］. Lung Cancer，2012，77（2）：365-370.
|
| 13 |
Makino T，Mikami T，Hata Y，et al. Comprehensive biomarkers for personalized treatment in pulmonary large cell neuroendocrine carcinoma：a comparative analysis with adenocarcinoma［J］. Ann Thorac Surg，2016，102（5）：1694-1701.
|
| 14 |
黄伟业，王千毓，何 娇，等.PD-L1 在肺大细胞神经内分泌癌中的表达和预后相关性及文献回顾［J］. 循证医学，2021，21（6）：364-371.
|
| 15 |
Hermans BCM，Derks JL，Thunnissen E，et al. Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma （LCNEC）［J］. Lung Cancer，2019，130：179-186.
|
| 16 |
Kim HS，Lee JH，Nam SJ，et al. Association of PD-L1 expression with tumor-infiltrating immune cells and mutation burden in highgrade neuroendocrine carcinoma of the lung［J］. J Thorac Oncol，2018，13（5）：636-648.
|
| 17 |
Sherman S，Rotem O，Shochat T，et al. Efficacy of immune checkpoint inhibitors （ICPi） in large cell neuroendocrine tumors of lung（LCNEC）［J］. Lung Cancer，2020，143：40-46.
|
| 18 |
Dudnik E，Kareff S，Moskovitz M，et al. Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung［J］. J Immunother Cancer，2021，9（2）：e001999.
|
| 19 |
Agar C，Geier M，Léveiller G，et al. Brief report on the efficacy of nivolumab in patients with previously treated advanced large-cell neuroendocrine cancer of the lung［J］. JTO Clin Res Rep，2020，2（4）：100129.
|
| 20 |
Song L，Zhou F，Xu T，et al. Clinical activity of pembrolizumab with or without chemotherapy in advanced pulmonary large-cell and large-cell neuroendocrine carcinomas：a multicenter retrospective cohort study［J］. BMC Cancer，2023，23（1）：443.
|
| 21 |
Shirasawa M，Yoshida T，Takayanagi D，et al. Activity and immune correlates of programmed death-1 blockade therapy in patients with advanced large cell neuroendocrine carcinoma ［J］. Clin Lung Cancer，2021，22（4）：282-291.e6.
|
| 22 |
Vrontis K，Economidou SC，Fotopoulos G. Platinum doublet plus atezolizumab as first-line treatment in metastatic large cell neuroendocrine carcinoma：a single institution experience ［J］.Cancer Invest，2022，40（2）：124-131.
|
| 23 |
Komiya T，Ravindra N，Powell E. Role of immunotherapy in stageⅣlarge cell neuroendocrine carcinoma of the lung［J］. Asian Pac J Cancer Prev，2021，22（2）：365-370.
|
| 24 |
谢明汛，龚明福，张 磊，等. 肺大细胞神经内分泌癌CT 表现及临床特征［J/CD］. 中华肺部疾病杂志（电子版），2022，15（2）：171-175.
|